Table 1.
Patient characteristics
| Characteristics | Numbers (N = 39) |
|---|---|
| Age (median, years) | 59 (range, 19–86) |
| Sex | |
| Male | 21 (53.8%) |
| Female | 18 (46.2%) |
| ECOG Performance status at radiation oncology department presentation | |
| 0–1 | 18 (46.2%) |
| 2 | 7 (17.9%) |
| Not reported | 14 (35.9%) |
| Primary site | |
| Lower extremity | 19 (48.7%) |
| Upper extremity | 5 (12.8%) |
| Uterus | 5 (12.8%) |
| Chest wall | 2 (5.1%) |
| Lung | 2 (5.1%) |
| Retroperitoneum | 2 (5.1%) |
| Buttock | 1 (2.6%) |
| Head and neck | 1 (2.6%) |
| Pelvis | 1 (2.6%) |
| Stomach | 1 (2.6%) |
| Histology | |
| Leiomyosarcoma | 9 (23.1%) |
| Osteosarcoma | 7 (17.9%) |
| Undifferentiated pleomorphic sarcoma | 5 (12.8%) |
| Liposarcoma | 4 (10.3%) |
| Synovial sarcoma | 4 (10.3%) |
| Chondrosarcoma | 2 (5.1%) |
| Myxofibrosarcoma | 2 (5.1%) |
| Spindle cell sarcoma | 2 (5.1%) |
| Alveolar soft part sarcoma | 1 (2.6%) |
| Ewing sarcoma | 1 (2.6%) |
| Malignant glomus tumor | 1 (2.6%) |
| Malignant peripheral nerve sheath tumor | 1 (2.6%) |
| Histological grade | |
| Not reported | 7 (17.9%) |
| 2 | 13 (33.3%) |
| 3 | 19 (48.7%) |
| History of surgery at primary site | 38 (97.4%) |
| Distant metastasis at initial diagnosis | 6 (15.4%) |
| Number of lung lesions at recurrence | |
| 1 | 19 (48.7%) |
| 2 | 8 (20.5%) |
| 3 | 4 (10.3%) |
| Numerous | 8 (20.5%) |
| Simultaneous extrathoracic metastasis | 16 (41.0%) |
| Indication of the first SBRT session | |
| Oligometastasis | 23 (59.0%) |
| Oligoprogression | 10 (25.6%) |
| Palliation | 6 (15.4%) |
| Progression-free interval | |
| ≤ 1 year | 29 (74.4%) |
| > 1 year | 10 (25.6%) |
| Total number of treated lung lesions by SBRT | |
| 1 | 20 (51.3%) |
| 2 | 8 (20.5%) |
| 3 | 6 (15.4%) |
| 4 | 4 (10.3%) |
| 5 | 1 (2.6%) |
| Patient status at last follow-up | |
| Alive with disease | 29 (74.4%) |
| No evidence of disease | 5 (12.8%) |
| Died of disease | 5 (12.8%) |
ECOG Eastern Cooperative Oncology Group; SBRT Stereotactic body radiation therapy